Karl W Oestreich (@KarlWOestreich)
Activity by Karl W Oestreich
Board Also Recognizes Four Recipients of Mayo Clinic Named Professorships
JACKSONVILLE, Fla., and ROCHESTER, Minn. — The Mayo Clinic Board of Trustees has named Gianrico Farrugia, M.D., Mayo Clinic vice president and chief executive officer of Mayo Clinic's campus in Jacksonville, Florida. Dr. Farrugia succeeds William Rupp, M.D., who will retire from Mayo Clinic at the end of 2014. The announcement was made today at the Mayo Clinic Board of Trustees quarterly meeting where the board also recognized four recipients of Mayo Clinic named professorships.
Soundbites of Dr. Noseworthy are available in the downloads box.
“Dr. Farrugia brings a wealth of experience to his new role,” says John Noseworthy, M.D., Mayo Clinic president and chief executive officer. “He is a physician-leader who brings to this important role a deep commitment to Mayo’s values, mission and strategic vision, along with a passion to lead and equip teams to reach more patients and strengthen Mayo Clinic’s position as a global health care leader. He has a strong commitment to continuing Dr. Rupp’s legacy of involvement and leadership in the Jacksonville community.”
Dr. Farrugia has been with Mayo Clinic for more than 26 years as a physician in the Division of Gastroenterology and Hepatology and Division of Physiology and Biomedical Engineering at Mayo Clinic’s campus in Rochester, Minnesota. He is also a professor of medicine as well as physiology and biomedical engineering. Dr. Farrugia has served in numerous leadership roles at Mayo Clinic with multisite responsibilities, both in his specialty and at the organizational leadership level. He currently serves as director of the Mayo Clinic Center for Individualized Medicine and director of Mayo Clinic’s Enteric Neuroscience Program. He previously served as research chair of the Department of Medicine.
In his new role, Dr. Farrugia will work with Bob Brigham, chief administrative officer in Florida, to provide leadership and direction, defining and implementing Mayo Clinic’s operational plan and continuing to expand Mayo Clinic’s leadership and reach in the Southeast and beyond.
ROCHESTER, Minn. — The Mayo Clinic Board of Trustees recognized four new named professorships, the highest academic distinction for faculty members at Mayo Clinic, during its quarterly meeting today.
Michael Brodsky, M.D., a physician with joint appointments in the Department of Neurology and Department of Ophthalmology, is recognized as the Knights Templar Eye Foundation, Inc. Professor in Ophthalmology Research. The Knights Templar Eye Foundation, incorporated in 1956, is a charity sponsored by the Grand Encampment of Knights Templar. The organization’s mission is to improve vision through research and education and by supporting access to care.
As a researcher, Dr. Brodsky focuses on evolutionary mechanisms of infantile strabismus (a condition in which the eyes are not properly aligned with one another); congenital optic disc anomalies; ocular motor physiology; nystagmus (a condition of involuntary eye movement acquired in infancy or later in life, that may result in reduced or limited vision); and other ocular motility disturbances. He has authored or co-authored several textbooks, including the definitive Pediatric Neuro-Ophthalmology.
He has also established a video-oculography laboratory at Mayo Clinic to study the role of binocular luminance disparity in infantile strabismus.
Douglas Husmann, M.D., Department of Urology, is recognized as the Anson L. Clark Professor in Urology. This professorship was established in 1974 by The Clark Foundation of Dallas, Texas, in memory of Anson L. Clark, M.D. Dr. Clark was a member of the Mayo Clinic staff in the section of special urology and an instructor in urology from 1931 to 1934.
As a urologist, Dr. Husmann’s clinical and research focus includes pediatric and reconstructive urology, and he has extensive experience in urologic reconstructive surgical procedures in both congenital abnormalities and traumatic injuries. He excels at translating basic science findings to the clinical arena. His work has resulted in numerous advances in the fields of androgen receptor physiology, the management of reproductive congenital abnormalities, traumatic genitourinary injuries and reconstructive urology.
Codina is executive chairman of Codina Partners, LLC, a real estate investment and development firm based in Coral Gables, Florida. Codina formed Codina Partners in 2009 and through this entity and its affiliates is engaged in multiple real estate development and investment activities. The firm’s portfolio includes mixed-used projects, commercial buildings and other investments primarily in Florida. Previously, Mr. Codina served as chairman of Flagler, a full-service commercial real estate firm headquartered in Coral Gables. The company’s portfolio spanned more than 12 million square feet of Class-A office and industrial space throughout Florida.
Taylor joined Wolfensohn Fund Management, New York, as managing director and a member of the fund’s Investment Committee in 2007. From 2003 to 2007, she was superintendent of banks for New York state, overseeing the regulation for over 3,500 financial institutions with assets totaling over $1.5 trillion. Before her appointment as superintendent, she worked for Gov. Pataki of the State of New York, and she started her career as an investment banker at Smith Barney, then Lehman, then Donaldson, Lufkin & Jenrette working on financing health and education facilities.
The Mayo Clinic Board of Trustees, a 31-member group of public representatives and Mayo Clinic physicians and administrators, is responsible for patient care, medical education and research at Mayo Clinic’s sites in Jacksonville, Fla.; Rochester, Minn.; and Phoenix and Scottsdale, Ariz.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.com and http://www.mayoclinic.org/news.
MEDIA CONTACT: Karl Oestreich, Mayo Clinic Public Affairs, 507-284-5005, email@example.com.
ROCHESTER, Minn. — To accelerate the pace of research, solve unmet needs of patients and improve the quality of health care, Mayo Clinic today announced a philanthropic campaign to raise $3 billion by Dec. 31, 2017, strengthening Mayo’s strategic priorities in patient care, research and education.
“Reliable funding is the biggest barrier to advance medical breakthroughs that can benefit patients suffering from diseases,” says John Noseworthy, M.D., Mayo Clinic president and CEO. “Traditional funding sources, such as federal grants, cannot cover the cost of discovering cutting-edge science and implementing those solutions in clinical practice.”
A focal point for the campaign is biomedical research. For example, funding will allow scientists and researchers to apply healthy tissues to regenerate and cure diseased organs; find trusted answers on diagnosis, prognosis and treatment of disease based on an individual’s genome and harness Mayo’s collective knowledge to improve the cost-effective delivery of quality health care.
ROCHESTER, Minn. — The Destination Medical Center Economic Development Agency (EDA) has selected the subconsultant team which will assist with the planning of the DMC Development Plan. The team includes:
“This world-class team of planners brings a broad base of experience with projects globally, nationally and throughout the state of Minnesota,” says Lisa Clarke, interim executive director, Destination Medical Center Economic Development Agency.
The subconsultants were evaluated based on the selection process approved by the Destination Medical Center Corporation (DMCC). Selections were made based on the experience of the firm, capabilities of the team proposed, knowledge of the market, and strength of their response to the request for proposal among other factors.
ROCHESTER, Minn. — Feb. 26, 2014 — As Mayo Clinic recognizes its Sesquicentennial year, the not-for-profit organization reached a record 63 million people in 2013. The strong performance was bolstered by successful implementation of new care delivery models — such as the Mayo Clinic Care Network — that provide knowledge to patients, physicians and consumers in traditional and new ways.
“Expanding our reach is not a new goal for us,” says John Noseworthy, M.D., Mayo Clinic president and CEO. “In fact, as we consider our history, growth has been a constant for 150 years.”
WHAT:An opportunity to ask questions about Mayo Clinic’s 2013 performance.
John Noseworthy, M.D.
President and CEO, Mayo Clinic
Vice President, Administration and CAO, Mayo Clinic
Noon CST/1 p.m. EST
Wednesday, Feb. 26, 2014
Audio news conference
PHOENIX — Feb. 21, 2014 — The Mayo Clinic Board of Trustees welcomed Samuel A. Di Piazza, Jr. as the new board chair and George Halvorson as a new member, recognized five retiring public members and three internal members who completed their tenure, and elected four new internal trustees.
Di Piazza replaces Marilyn Carlson Nelson, who is retiring from the board. Di Piazza recently announced that he was leaving Citi as vice chairman and a member of the Senior Client Executive Group to serve as Mayo Clinic’s Board of Trustees chair. Di Piazza joined the Mayo board in 2010. He joined Citi in May 2011 after a long career at PricewaterhouseCoopers as a partner and, ultimately, CEO from 2002 through 2009.